Dr. Chris Castel

Dr. Chris Castel

Dr. Chris Castel

CEO-CTO | CareWear

    Chris Castel PhD received his PhD at Showa University in Tokyo, Japan in Physical Medicine and Rehabilitation Research. His expertise is in the development, regulatory approval and commercialization of therapeutic medical devices for physical medicine, rehabilitation, and wound healing. Dr. Castel has and continues to manage numerous clinical trials for energy delivery medical devices in the fields of PBM, Ultrasonics, Electrotherapy, and PEMF. His previous company’s products and services were deployed in over 6,000 post-acute care facilities nationwide and provided advanced technologies for pain management, stroke recovery, wound care, and incontinence management. He has extensive experience in the medical device regulatory approval process with the FDA, national and international regulatory agencies and oversaw the process and obtained positive national coverage determinations from CMS for Electrotherapy devices in wound healing and incontinence management, along with a team of professional associations and industry leaders. Having founded and sold three medical device companies successfully to major strategic partners, he became interested in, and established a new venture, CareWear, to develop patient-oriented therapeutic wearables which use breakthrough technologies such as printed light and ultrasonic substrates. CareWear was a 2018 SPIE Startup Challenge winner. Dr. Castel is a NAALT Board member and is active in the association. Dr. Castel holds numerous patents and has published extensively. As an international lecturer, he has taught and presented at a post-graduate global level in such areas as neurorehabilitation, pain management, LLLT – PBM, Magnetic Field Therapy and Ultrasonics. He was one of the first researchers during the 1980s to publish the effects of infrared and red light on collagen synthesis and has spent his career developing new technologies to treat pain and accelerate healing. He looks forward to bringing PBM to mainstream medicine.